In this investigation, we presented the first demonstration that FUBP1 overexpression confers lobaplatin resistance, whereas FUBP1 knockdown increases lobaplatin sensitivity in human osteosarcoma both in vitro and in vivo. This evidence concerns the gene FUBP1 and osteosarcoma.